Clinical Trial · NCT03083288

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer

Overview

Up to 30 evaluable participants with known or suspected breast cancer (BIRADS 5 by imaging) will undergo FTT PET/CT imaging before primary surgery or neoadjuvant therapy. Patients undergoing neoadjuvant therapy may choose to have a second FTT PET/CT scan after the start of therapy (1 days to 3 weeks). FTT PET/CT uptake will be correlated with pathology measures and treatment response, in subjects undergoing neoadjuvant therapy

Sponsor

Abramson Cancer Center of the University of Pennsylvania

Phase

Phase 1

Contacts

Elizabeth McDonald, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03083288

Drug / Compound

FluorThanatrace

Isotope(s):

Target(s):

PARP

Ligand Class: Small Molecules

Eligibility

Inclusion

At least one breast lesion one breast lesion that is 1 cm or greater in size by standard imaging (e.g. mammography, ultrasound or breast MRI). Only one type of imaging is required to show a lesion of 1 cm or greater in order for the patient to be eligible to participate in this study. Patients that have a prior diagnosis of primary breast cancer in the opposite breast can be included.
Known or suspected (BIRADS 5 on imaging) primary breast cancer
Willing to allow use orcollection of pathology tissue for the purposes of research from either clinical biopsy or surgical procedure (if adequate tissue is available) or research only biopsy

Exclusion

Exclusion criteria not yet provided.